Major players in the neurodegenerative disorder therapeutics market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd., ACADIA Pharmaceuticals Inc., Lundeck A/S, Boehringer Ingeiheim International GmbH, Merck Serono, Orion Pharma Ltd., Mitsubishi Tanabe Pharma America, Allergan, GlaxoSmith Kline PLC., AbbVie, Eli lilly, Celgene, Neuro- Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation, AstraZeneca, Alector, Yumanity Therapeutics, Yangtze River Pharmaceutical Group, Chongqing Zein Pharmaceutical and Eisai.
The global neurodegenerative disorder therapeutics market is expected to grow from $14.66 billion in 2021 to $15.86 billion in 2022 at a compound annual growth rate (CAGR) of 8.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $21.66 billion in 2026 at a CAGR of 8.1%.
The neurodegenerative disorder therapeutics market consists of sales of neurodegenerative disorder therapeutics products and related services for neurodegenerative disorders.Neurodegenerative disorder is a range of incurable conditions that primarily affect the neurons of human brain and results in progressive degeneration or death of nerve cells.
The neurodegenerative disorder therapeutics deals with the manufacturing and development of drugs and treatment that stops or slows down the neurodegenerative processes of diseases such as Parkinson’s, Alzheimer’s, Huntington’s and other neurodegenerative disorders.
The main drug types of neurodegenerative disorder therapeutics are n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors and others. selective serotonin reuptake inhibitors are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various indication include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington disease and other indications that ARE distributed through hospital pharmacy, retail pharmacy, online pharmacy.
North America was the largest region in the neurodegenerative disorder therapeutics market in 2021.Middle East is expected to be the fargest growing region in the forecast period.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Increased prevalence of neurodegenerative among the global population contributes to the growth of neurodegenerative disorder therapeutics market.The increase in the number of geriatric population, attributes to the increased prevalence of neurodegenerative disorders.
According to World Population Prospects, the number of people above 60 years of age will increase to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering with Alzheimer disease and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the ageing population increases the demand for neurodegenerative disorder therapeutics thereby driving the market.
High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market.Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently very few treatments are approved for neurodegenerative disorders.
According to a study in 2019, there are officially 112 new molecular entities in Alzheimer’s disease (AD) clinical trials, although there are 3558 in cancer trials.For instance, 12 of the 42 (28 per cent) drugs certified by the US Food and Drug Administration (FDA) were oncology therapies, this compares with 0% of AD drugs in production.
This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate at 81%. Moreover, as reported by The New England Journal of Medicine, no new drug has been approved by the Food and Drug Administration (FDA) to treat Alzheimer’s disease since 2013. The low rate of approval of neurodegenerative therapeutics has a negative impact on the market, hindering the growth of the market.
Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non- government organizations to discover and develop therapeutics for a range of neurodegenerative diseases.The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market in order to increase their capabilities for research and development activities in order to develop new and more effective therapeutic solutions to treat neurodegenerative disorders.
For instance, from October 2019, Prevail Therapeutics Inc., a USA based biotechnology company and Lonza, a global supplier of pharma & Biotech and specialty ingredients based in Switzerland, collaborated to develop and manufacture gene therapy programs for patients of neurodegenerative diseases. Similarly, Abbevie, a USA based biopharmaceutical company and Voyager Therapeutics, a clinical stage gene therapy company based in USA, underwent a global strategic collaboration to develop and commercialize treatments for Alzheimer’s disease and other tau-related (a protein) neurodegenerative diseases.
In January 2020, Biogen Inc., an America Biotechnology company acquired a novel clinical stage asset, PF-05251749 alongwith the applications from Pfizer for $75 million. The acquisition of the asset is expected to strengthen Biogen’s existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases since PF-05251749 is a CNS- penetrant regulator that has the potential to treat behavioral and neurological symptoms across various psychiatric and neurological diseases. Pfizer Inc., is a multinational pharmaceutical company based in the USA.
The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
Our reports have been used by over 10K customers, including:
The global uveitis treatment market reached a value of US$ 1.5 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 2.2 Billion by 2027, exhibiting a CAGR of 5.95% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence...
120 pages •
By Infiniti Research Limited
• May 2022
Global Throat Cancer Therapeutics Market 2022-2026 The analyst has been monitoring the throat cancer therapeutics market and it is poised to grow by $ 1.82 bn during 2022-2026, accelerating at a CAGR of 6.7% during the forecast period. Our report on the throat cancer therapeutics market provides a holistic analysis, market...
Female Hypoactive Sexual Desire Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder - Drugs In Development, 2022, provides an overview...
Fibrosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Fibrosarcoma - Drugs In Development, 2022, provides an overview of the Fibrosarcoma (Oncology) pipeline landscape. Fibrosarcoma...
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 220.127.116.11) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 18.104.22.168) pipeline Target constitutes...
266 pages •
By Future Market Insight Global & Consulting Pvt Ltd
• Apr 2022
A recent market study published on the bacteriophage market offers a global industry analysis for 2016-2020 and an opportunity assessment for 2020-2031. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of...
Crigler-Najjar Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Crigler-Najjar Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players,...
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 22.214.171.124) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Proto Oncogene Tyrosine Protein Kinase...
115 pages •
By Transparency Market Research
• Apr 2022
Saudi Arabia Veterinary Therapeutics Market – Scope of Report This report on the veterinary therapeutics market in Saudi Arabia studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031.The report provides...
Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.